Semaglutide vs Tirzepatide
Which GLP-1 medication is right for you?
Last updated: 2024-12-01
Semaglutide
GLP-1 receptor agonist. Brand names: Ozempic (diabetes), Wegovy (weight loss). Made by Novo Nordisk.
Tirzepatide
Dual GIP/GLP-1 receptor agonist. Brand names: Mounjaro (diabetes), Zepbound (weight loss). Made by Eli Lilly.
Side-by-Side Comparison
Activates GLP-1 receptors only. Well-established, understood mechanism.
Activates both GIP and GLP-1 receptors. The GIP component may provide additional benefits.
STEP trials showed 14.9% weight loss at 68 weeks with lifestyle intervention.
SURMOUNT-1 showed up to 22.5% weight loss at highest dose. Generally superior results.
Ozempic approved 2017. Wegovy approved 2021 for chronic weight management.
Mounjaro approved 2022. Zepbound approved late 2023 for weight management.
Start at 0.25mg, titrate up to 2.4mg (Wegovy) over ~16-20 weeks.
Start at 2.5mg, titrate up to 15mg (Zepbound) over ~20 weeks.
Nausea (40-50%), diarrhea, constipation, vomiting. Usually improve over 4-8 weeks.
Similar nausea rates. Some studies suggest GI side effects may be slightly more common initially.
Brand name without insurance. Compounded versions available at $200-500/month.
Brand name without insurance. Compounding less common as it's newer.
Had major shortages in 2022-2023. Supply stabilizing but some doses still limited.
Better availability overall, though demand is high.
More long-term safety data. Cardiovascular benefits shown in trials.
Newer medication. Long-term data still accumulating. Early CV trial results are promising.
A1c reduction of 1.5-2%. Strong evidence for diabetes management.
A1c reduction of 2-2.5%. Studies show better glycemic control than semaglutide.
Both medications are highly effective for weight loss and represent the most powerful options available today. Tirzepatide (Mounjaro/Zepbound) shows slightly better weight loss results in clinical trials, averaging about 20-22% body weight loss compared to semaglutide's 15-17%. However, semaglutide (Ozempic/Wegovy) has been on the market longer and has more long-term safety data, including proven cardiovascular benefits.
For most people, either medication would be a good choice. The "best" option often comes down to insurance coverage, availability, cost, and personal response. Some people who don't respond well to one medication do well on the other.
Which Is Right for You?
- You want a medication with a longer track record
- Your insurance covers Wegovy/Ozempic but not Zepbound/Mounjaro
- You prefer the option of compounded semaglutide for cost savings
- Cardiovascular protection is a priority (proven in trials)
- You're satisfied with 15-17% weight loss potential
- Maximum weight loss is your primary goal
- You have type 2 diabetes and want the best blood sugar control
- You haven't responded well to semaglutide
- Your insurance covers Zepbound/Mounjaro
- You're comfortable with a newer medication with less long-term data
Important Note
This comparison is for educational purposes only and should not replace medical advice. The best medication for you depends on your individual health profile, medical history, and personal circumstances. Always consult with a healthcare provider who can evaluate your specific situation before starting any medication.